title: Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride.
abstract: The purpose of this study was to develop and manufacture novel freeze-dried orally disintegrating tablets (ODTs) for migraine therapy containing taste-masked naproxen sodium and naratriptan hydrochloride. The formulation was optimized based on freeze-drying of sucrose solutions with different binders (hydroxyethylstarch, sodium alginate, methylcellulose, and gelatin) and varying amounts of Eudragit® E-coated naproxen sodium granules. Excellent product performance of the ODTs in terms of hardness and disintegration time (<10 s) independent of the mass of particles embedded was found for the solution consisting of sucrose and hydroxyethylstarch. Poloxamer 188, menthol flavor, naratriptan hydrochloride, and taste-masked naproxen sodium granules corresponding to 200 mg of naproxen were then added, and the final batches of ODTs for migraine therapy were produced. The ODTs were fully characterized, and subsequently stored for 1 month at room temperature and at 40°C. The amount of free naproxen sodium after freeze-drying and storage was below the threshold bitterness value, and the coating remained intact. Additionally, the particle size distribution of taste-masked granules was preserved, and more than 90 % naproxen sodium was released after 30 min. Naratriptan hydrochloride was dissolved immediately after disintegration, hence facilitating buccal absorption of the active pharmaceutical ingredient.
authors: Freeze Drying Focus Group (FDFG), Division of Pharmaceutics, University of Erlangen, Erlangen, 91058, Germany.
authors: Ulrike
authors: U
authors: Stange
authors: Christian
authors: C
authors: Führling
authors: Henning
authors: H
authors: Gieseler
mesh_terms: D000284:Administration, Oral; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry*; D004339:Drug Compounding; D004356:Drug Storage; D005079:Excipients / Q000737:chemistry*; D005612:Freeze Drying; D008881:Migraine Disorders / Q000188:drug therapy; D009288:Naproxen / Q000737:chemistry*; D010316:Particle Size; D010880:Piperidines / Q000737:chemistry*; D011109:Polymethacrylic Acids / Q000737:chemistry; D012995:Solubility; D013607:Tablets; D013649:Taste; D014363:Tryptamines / Q000737:chemistry*; D014662:Vasoconstrictor Agents / Q000737:chemistry*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005079:Excipients; D010880:Piperidines; D011109:Polymethacrylic Acids; D013607:Tablets; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C038300:methylmethacrylate-methacrylic acid copolymer; D009288:Naproxen; C106783:naratriptan
keywords: excipients; fast melting tablet; formulation; freeze drying/lyophilization; microparticles; migraine; oral drug delivery; orally disintegrating tablet; taste masking